PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS CGAS INHIBITORS

PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS CGAS INHIBITORS

The invention relates to new proline derivatives of formula (I) as cGAS inhibitors, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compounds for the treatment of diseases such as systemic lupus erythema...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: HOENKE, CHRISTOPH, GROSS, PATRICK, REINERT, DIRK, STUBER, RAPHAEL, KLEY, JOERG, GNAMM, CHRISTIAN, KUTTRUFF, CHRISTIAN ANDREAS, GRUNDL, MARC ALEXANDER, GODBOUT, CEDRICKX, THEIS, THEODOR, HEIMANN, ANNEKATRIN CHARLOTTE, HANDSCHUH, SANDRA RUTH
Format: Patent
Sprache:eng ; fre
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The invention relates to new proline derivatives of formula (I) as cGAS inhibitors, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compounds for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF). L'invention se rapporte à de nouveaux dérivés de proline de formule (I) en tant qu'inhibiteurs de cGAS, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 et G étant définis dans la revendication 1, et des promédicaments ou des sels pharmaceutiquement acceptables de ces composés destinés au traitement de maladies telles que le lupus érythémateux disséminé, la sclérose systémique (SSc), la stéatose hépatique non alcoolique (NASH), la maladie pulmonaire interstitielle (ILD) et la fibrose pulmonaire idiopathique (FPI).